Media coverage about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has trended somewhat positive recently, according to Alpha One Sentiment Analysis.
The company reported an impressive total revenue of 6.47 Million in the last fiscal year. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.
ATR value of company was 0.53. Sterling Global Strategies LLC now owns 42,600 shares of the specialty pharmaceutical company's stock valued at $181,000 after buying an additional 2,600 shares during the last quarter. The analysts estimated EPS for the higher end at -0.13 and lower end at -0.13 while the year ago reported earnings per share was -0.13.
Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock.
Adamis Pharmaceuticals Corporation (ADMP) traded down 6.827% during midday trading on Friday, reaching $4.845.
EPS growth in past 5 year was -5.30%.
When it comes to the Analysis of a Stock, Price Target plays a vital role.
Ocado Group PLC 28.7% Potential Decrease Indicated by Deutsche Bank
Leerink Swann reissued an "outperform" rating on shares of AstraZeneca plc in a research note on Monday, March 20th. Beaufort Securities maintained the shares of TSCO in report on Friday, January 15 with "Hold" rating.
Taking a broader look brokerage firms' analysts on the street with an expectant view have Adamis Pharmaceuticl (NASDAQ:ADMP) high price target of $10 and with a conservative view have low price target of $10.
While looking at the Stock's Performance, Adamis Pharmaceuticals Corporation now shows a Weekly Performance of 20.93%, where Monthly Performance is 42.47%, Quarterly performance is 14.29%, 6 Months performance is 70.49% and yearly performance percentage is 68.28%.
The simple moving average is the most common method used to calculate the moving average of prices. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 25.49% where SMA50 and SMA200 are 27.34% and 51.07% respectively. The company's stock had a trading volume of 4,880,783 shares. The company has a Return on Assets (ROA) of -58.70%.
Adamis Pharmaceuticals Corporation (ADMP) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 14.03 P/E and the sector P/E is 19.01. The return on invested capital at -63.1%, which is good, compared to its peers. Over the last six months, Adamis Pharmaceuticals Corporation's stock has been 61.90% and 68.32% for the year.
ROE ratio is a measure of profitability which calculates how much dollars of profit a firm makes with every dollar of stakeholder's equity. The market capitalization of the company is at $155.45 Million.
Zacks offers analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations.
Now the shares of Adamis Pharmaceuticals Corporation (ADMP) has the trading volume of 18.7 Million shares with the average trading volume of 5460 shares.